Country for PR: United Kingdom
Contributor: PR Newswire Europe
Thursday, April 01 2021 - 09:18
AsiaNet
Alfasigma: It's Vein Week from 5th to 11th of April
BOLOGNA, Italy, April 1, 2021 /PRNewswire-AsiaNet/ --

- v-WIN Foundation and Alfasigma together to fight one of the leading causes of 
preventable death: venous thrombosis 

- Italy as the hub of an international public awareness project on venous and 
lymphatic health of the legs to be presented in DUBAI during the EXPO 

- An innovative geo-localization software has being launched to increase 
knowledge & awareness about the disease 


Venous-lymphatic World International Network foundation (v-WIN), a no profit 
global organization dedicated to research and education in the venous & 
lymphatic field has developed a public and health professional awareness 
not-for-profit project called VEIN WEEK, entirely dedicated to vein & lymphatic 
management advancement.

Logo - https://mma.prnewswire.com/media/1325576/Alfasigma_Logo.jpg   

The project, connecting experts, patients & public from all around the world, 
will run during the Health Week, planned from April 5th to April 11th, which 
will include April 7th World Health Day. Among the supporters of the 
not-for-profit educational initiative, also the Italian company Alfasigma. 

A dedicated open access software has been made available for all the health 
professionals and public wishing to add their own initiatives aimed at 
increasing venous-lymphatic awareness. More than 200 activities have been 
already added from all around the world.

These activities will follow a common calendar in which every day is dedicated 
to a specific task: Monday for specialists, Tuesday for patients, Wednesday for 
media, Thursday for clinical work, Friday for multi-specialty involvement, 
Saturday and Sunday for social and sport initiatives promoting venous health.

The initiative has been designed and developed by a group of international top 
experts representing all continents.

Among many others organizations and institutions endorsement, the initiative is 
under the auspices also of the Italian Board of Physicians (FNOMCEO).

The initiative is of paramount importance considering it is dealing with 
venous-lymphatic disease: a condition affecting more than half of the 
population, related to venous-thromboembolism which is a leading cause of 
preventable death, to lymphedema which is considered a "hidden epidemic," to 
pelvic venous disorders which are considered a "not to be forgotten" condition. 
All details are available on the foundation website 
(www.vwinfoundation.com/vw). 

"Venous-thromboembolism is one of the leading causes of preventable death, 
lymphedema is considered a hidden epidemic, pelvic pain potentially associated 
with venous reflux is more frequent than asthma and back pain," says dr. Sergio 
Gianesini, as President of Venous-lymphatic World International Network 
Foundation (v-WIN Foundation), focusing on the relevance of vein & lymphatic 
management advancement in particular during COVID pandemic, when these kind of 
complications represent one of the most common challenges. 

Geolocalization pages will remain also after the Vein Week 
(https://veinweek.vwinfoundation.com)  in order to share events, initiatives, 
projects in this therapeutic area. 

Pier Vincenzo Colli, CEO of Alfasigma declares: "Alfasigma is proud to support 
Vein Week project, giving visibility to local educational and scientific 
initiatives on a global level. A great number of events has already been 
uploaded autonomously from all parts of the world and each of these can be 
customized with videos, interviews and other presentation content." 

This effort is part of the digital transformation project of Alfasigma, that 
aims to develop more sustainable and digital connection all around the world.  

"The objective of Vein Week 2021 is to raise awareness of venous and lymphatic 
disorders throughout the global medical community with particular focus on 
regions traditionally lack healthcare resources - due to paucity of economic 
parity and ongoing conflicts." affirms dr. Yung Wei Chi founder and member of 
v-WIN Foundation Board who concludes "Venous and lymphatic disorder is one of 
the most common healthcare conditions worldwide irrespective of the pandemic. 
However the pandemic have overshadowed many other disease entities and 
associated campaigns. To put it in perspective, venous and lymphatic disorder 
is closely linked to the complications of COVID-19 i.e. venous thrombosis. A 
dedicated campaign focusing on raising the awareness of venous and lymphatic 
disorder in addition to its association with COVID complication in time of this 
global pandemic is paramount to the care of those who suffered from the 
ailment."

v-WIN Foundation 
The vWIN has been created by an idea of Sergio Gianesini, Oscar Bottini and 
Yung-Wei Chi, three vein specialists working in three different universities of 
three different continents, with the idea of adhering the medical and public 
world together for health and science promotion. World renowned physicians and 
scientists are part of the scientific committee. Venous-lymphatic World 
International Network foundation (v-WIN) is a worldwide non-profit organization 
dedicated to improving the management of venous and lymphatic pathology. The 
foundation operates in 3 main areas of action:

- scientific research and educational activity
- humanitarian medical missions
- social and sports activities promoting venous and lymphatic health awareness;

More info on the website:  https://veinweek.vwinfoundation.com 

Alfasigma
Privately owned, Alfasigma is one of the leading Italian pharmaceutical 
companies, present in over 90 countries, through distributors and subsidiaries 
and has a workforce of around 3,000 people, R&D laboratories, and 5 production 
plants. 

In Italy, Alfasigma is a leader in the market for prescription products where, 
in addition to the strong focus on gastrointestinal and vascular areas, it is 
present in many primary care therapeutic areas. Alfasigma also produces and 
markets self-medication products, nutraceuticals and food supplements. 

More information is available at the corporate website 
https://www.alfasigma.com    
 
SOURCE  Alfasigma


Translations

Japanese